Corneal toxicity from topical ocular and systemic medications

Cornea

Volumn 25, Issue 10, 2006, Pages 1133-1138

  Fraunfelder, F W ^a,b,c,d  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

^c Casey Eye Institute and the National Registry of Drug Induced Ocular Side Effects   (United States)

^d CASEY EYE INSTITUTE   (United States)

Author keywords

Corneal toxicity; Drug induced ocular side effects; Herbal medicines; Pharmacology

Indexed keywords

AINEX; ALENDRONIC ACID; AMINOGLYCOSIDE ANTIBIOTIC AGENT; APRACLONIDINE; BETAXOLOL; BISPHOSPHONIC ACID DERIVATIVE; BRIMONIDINE; BRINZOLAMIDE; CELECOXIB; CIPROFLOXACIN; CLODRONIC ACID; CYCLOOXYGENASE 2 INHIBITOR; CYTARABINE; DIAZEPAM; DICLOFENAC; DORZOLAMIDE; ENZON; ETIDRONIC ACID; ETODOLAC; ETRETIN; ETRETINATE; FLUOROURACIL; GATIFLOXACIN; GENTAMICIN; HERBACEOUS AGENT; IBANDRONIC ACID; IMATINIB; ISOTRETINOIN; KETOROLAC TROMETAMOL; LATANOPROST; LEVOBUNOLOL; LOCAL ANESTHETIC AGENT; LUMIRACOXIB; MITOMYCIN C; MOXIFLOXACIN; NONSTEROID ANTIINFLAMMATORY AGENT; POVIDONE IODINE; PREDNISOLONE ACETATE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RETINOIC ACID; RETINOID DERIVATIVE; RISEDRONIC ACID; ROFECOXIB; STEROID; SUPERGEN; TILUDRONIC ACID; TIMOLOL; TIMOLOL MALEATE; TOBRAMYCIN; TRAVOPROST; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALDECOXIB; ZOLEDRONIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; BLEEDING TENDENCY; BRASSICA; CALCIUM BONE LEVEL; CATARACT EXTRACTION; CONJUNCTIVA DISEASE; CONJUNCTIVITIS; CONTACT DERMATITIS; CORNEA; CORNEA DISEASE; CORNEA EPITHELIUM; CORNEA LESION; CORNEA NEOVASCULARIZATION; CORNEA OPACITY; CORNEA TUMOR; DRUG CYTOTOXICITY; DRUG WITHDRAWAL; DRY EYE; EPISCLERITIS; EUPHORBIA; EYE DISEASE; EYE INFLAMMATION; EYE IRRITATION; FOOD AND DRUG ADMINISTRATION; HERBAL MEDICINE; HUMAN; INFLAMMATION; INFLAMMATORY DISEASE; INFORMATION PROCESSING; KERATITIS; KERATOCONJUNCTIVITIS; KERATOMILEUSIS; LACRIMAL DUCT OCCLUSION; MATRICARIA; MEDLINE; MENOPAUSAL SYNDROME; PERFORATING EYE INJURY; PERIORBITAL EDEMA; PHOTOPHOBIA; PLANTAGO OVATA; POSTOPERATIVE INFLAMMATION; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; SCLERA DISEASE; SCLERITIS; SIDE EFFECT; TOPICAL ANESTHESIA; UVEITIS; WORLD HEALTH ORGANIZATION; WOUND HEALING;

CORNEA; CORNEAL DISEASES; FEMALE; HUMANS; MALE; PHARMACEUTICAL PREPARATIONS; PHYTOTHERAPY; PLANT EXTRACTS; PRESERVATIVES, PHARMACEUTICAL;

EID: 33845803166     PISSN: 02773740     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ico.0000240084.27663.fd     Document Type: Review

References (79)

1. Bettman JW. Seven hundred medicolegal cases in ophthalmology. Ophthalmology. 1990;97:1379-1384.
2. Brick DC. Medication errors result in costly claims for ophthalmologists. Surv Ophthalmol. 1995;40:232-236.
3. World Health Organization. International Drug Monitoring: The Role of the Hospital. Geneva, Switzerland: World Health Organization; 1966.
4. Fraunfelder FT, Fraunfelder FW. Drug-Induced Ocular Side Effects. 5th ed. Woburn, MA: Butterworth-Heinemann; 2001.
5. Bridges WZ, Palay DA. Corneal deposits. In: Krachmer JH, Mannis MJ, Holland EJ, eds. Cornea: Fundamentals of Cornea and External Disease. Vol. 1. St Louis: Mosby; 1997:417-426.
6. Stern GA, Schemmer GB, Farber RD, et al. Effect of topical antibiotic solutions on corneal epithelial wound healing. Arch Ophthalmol. 1983;101:644-647.
7. Bullard SR, O'Day DM. Pseudomembranous conjunctivitis following topical gentamicin therapy. Arch Ophthalmol. 1997;115:1591-1592.
8. Petroutsos G, Guimaraes R, Giraud J, et al. Antibiotics and corneal epithelial wound healing. Arch Ophthalmol. 1983;101:1775-1778.
9. Fraunfelder FW, Fraunfelder FT. Bisphosphonates and ocular inflammation. N Engl J Med. 2003;348:1187-1188.
10. Fraunfelder FW. Ocular side effects associated with bisphosphonates. Drugs Today. 2003;39:829-835.
11. Fraunfelder FW, Fraunfelder FT. Adverse ocular drug reactions recently identified by the National Registry of Drug-Induced Ocular Side Effects. Ophthalmology. 2004;111:1275-1279.
12. Pfister RR. Permanent corneal edema resulting from the treatment of PTK corneal haze with mitomycin. Cornea. 2004;23:744-747.
13. Fujitani A, Hayasaka S, Shibuya Y, et al. Corneoscleral ulceration and corneal perforation after pterygium excision and topical mitomycin C therapy. Ophthalmologica. 1993;207:162-164.
14. Hickey-Dwyer M, Wishart PK. Serious corneal complication of 5-fluorouracil. Br J Ophthalmol. 1993;77:250-251.
15. Knapp A, Heuer DK, Stern GA, et al. Serious corneal complications of glaucoma filtering surgery with postoperative 5-fluorouracil. Am J Ophthalmol. 1987;103:183-187.
16. Lochhead J, Salmon JF, Bron AJ. Cytarabine-induced corneal toxicity. Eye. 2003;17:677-678.
17. Lass JH, Lazarus HM, Reed MD, et al. Topical corticosteroid therapy for corneal toxicity from systemically administered cytarabine. Am J Ophthalmol. 1982;94:617-621.
18. Esmaeli B, Diba R, Ahmadi MA, et al. Periorbital oedema and epiphora as ocular side effects of imatinib mesylate (Gleevec). Eye. 2004;18:760-762.
19. Fraunfelder FW, Solomon J, Druker BJ. Ocular side-effects associated with imatinib mesylate (Gleevec). J Ocul Pharmacol Ther. 2003;19:371-375.
20. Fraunfelder FW, Solomon J, Mehelas TJ. Ocular adverse effects associated with cyclooxygenase-2 inhibitors. Arch Ophthalmol. 2006;124:277-279.
21. Lutz EG. Allergic conjunctivitis due to diazepam. Am J Psychiatry. 1975;132:548.
22. Fraunfelder FW. Ocular side effects associated with isotretinoin. Drugs of Today. 2004;40:23-27.
23. Fraunfelder FT, Fraunfelder FW, Edwards R. Ocular side effects possibly associated with isotretinoin usage. Am J Ophthalmol. 2001;132:299-305.
24. Goldberg D, Panigrahi D, Barazi M, et al. A case of rofecoxib-associated Stevens-Johnson syndrome with corneal and conjunctival changes. Cornea. 2004;23:736-737.
25. Essepian JP, Rajpal R, O'Brien TP. Tandem scanning confocal microscopic analysis of ciprofloxacin corneal deposits in vivo. Cornea. 1995;14:402-407.
26. Eiferman RA, Snyder JP, Nordquist RE. Ciprofloxacin microprecipitates and macroprecipitates in the human corneal epithelium. J Cataract Refract Surg. 2001;27:1701-1702.
27. Wilhelmus KR, Abshire RL. Corneal ciprofloxacin precipitation during bacterial keratitis. Am J Ophthalmol. 2003;136:1032-1037.
28. Wilhelmus KR, Hyndiuk RA, Caldwell DR, et al. 0.3% ciprofloxacin ophthalmic ointment in the treatment of bacterial keratitis. The Ciprofloxacin Ointment/Bacterial Keratitis Study Group. Arch Ophthalmol. 1993;111:1210-1218.
29. Awwad ST, Haddad W, Wang MX, et al. Corneal intrastromal gatifloxacin crystal deposits after penetrating keratoplasty. Eye Contact Lens. 2004;30:169-172.
30. Gokhale NS. Sparfloxacin corneal deposits. Indian J Ophthalmol. 2004;52:79.
31. Patel GM, Chuang AZ, Kiang E, et al. Epithelial healing rates with topical ciprofloxacin, ofloxacin, and ofloxacin with artificial tears after photorefractive keratectomy. J Cataract Refract Surg. 2000;26:690-694.
32. Moreira LB, Lee RF, de Oliveira C, et al. Effect of topical fluoroquinolones on corneal re-epithelialization after excimer laser keratectomy. J Cataract Refract Surg. 1997;23:845-848.
33. Inoue K, Okugawa K, Kato S, et al. Ocular factors relevant to antiglaucomatous eyedrop-related keratoepitheliopathy. J Glaucoma. 2003;12:480-485.
34. Plane C, Boulmier A. Long-term treatment of chronic glaucoma with timolol drops: results after four years. J Fr Ophthalmol. 1981;4:751-756.
35. Taguri AH, Khan MA, Sanders R. Marginal keratitis: an uncommon form of topical dorzolamide allergy. Am J Ophthalmol. 2000;130:120-122.
36. Konowal A, Morrison JC, Brown SV, et al. Irreversible corneal decompensation in patients treated with topical dorzolamide. Am J Ophthalmol. 1999;127:403-406.
37. Grant WM. An iodine vapor applicator for treatment of dendritic keratitis. Arch Ophthalmol. 1952;48:749-751.
38. Tripathi RC, Tripathi BJ. Pathology of drug-induced and toxic diseases. In: Riddel RH, ed. The Eye. London: Churchill Livingstone; 1982:405-406.
39. Fraunfelder FW, Rich LF. Possible adverse effects of drugs used in refractive surgery. J Cataract Refract Surg. 2003;29:170-175.
40. Guidera AC, Luchs JI, Udell IJ. Keratitis, ulceration, and perforation associated with topical nonsteroidal anti-inflammatory drugs. Ophthalmology. 2001;108:936-944.
41. Tomas-Barberan S, Fagerholm P. Influence of topical treatment on epithelial wound healing and pain in the early postoperative period following photorefractive keratectomy. Acta Ophthalmol Scand. 1999;77:135-138.
42. Hersh PS, Rice BA, Baer JC, et al. Topical nonsteroidal agents and corneal wound healing. Arch Ophthalmol. 1990;108:577-583.
43. Collin HB, Carroll N. Ultrastructural changes to the corneal endothelium due to benzalkonium chloride. Acta Ophthalmol (Copenh). 1986;64:226-231.
44. Palmer RM, Kaufman HE. Tear film, pharmacology of eye drops, and toxicity. Curr Opin Ophthalmol. 1995;6:11-16.
45. Tippermann R, ed. Physicians' Desk Reference for Ophthalmic Medicines. 30th ed. Montvale, NJ: Medical Economics; 2002.
46. Tripathi BJ, Tripathi RC, Kolli SP. Cytotoxicity of ophthalmic preservatives on human corneal epithelium. Lens Eye Toxic Res. 1992;9:361-375.
47. Fraunfelder FT, LaBraico JM, Meyer SM. Adverse ocular reactions possibly associated with isotretinoin. Am J Ophthalmol. 1985;100:534-537.
48. Rismondo V, Ubels JL. Isotretinoin in lacrimal gland fluid and tears. Arch Ophthalmol. 1987;105:416-420.
49. Blackman HJ, Peck GL, Olsen TG. Blepharoconjunctivitis: a side effect of 130-cis-retinoic acid therapy for dermatologic diseases. Ophthalmology. 1979;86:753-758.
50. Weiss J, Degnan M, Leupold R, et al. Bilateral corneal opacities. Occurrence in a patient treated with oral isotretinoin. Arch Dermatol. 1981;117:182-183.
51. Ellies P, Dighiero P, Legeais JM, et al. Persistent corneal opacity after oral isotretinoin therapy for acne. Cornea. 2000;19:238-239.
52. Epstein DL, Paton D. Keratitis from misuse of corneal anesthetics. N Engl J Med. 1968;279:393-399.
53. Pharmakakis NM, Katsimpris JM, Melachrinou MP, et al. Corneal complications following abuse of topical anesthetics. Eur J Ophthalmol. 2002;12:373-378.
54. Varga JH, Rubinfeld RS, Wolf TC, et al. Topical anesthetic abuse ring keratitis: report of four cases. Cornea. 1998;16:424-429.
55. Duffin RM, Olson RJ. Tetracaine toxicity. Ann Ophthalmol. 1984;16:836-838.
56. Burns RP. Toxic effects of local anesthetics. JAMA. 1978;240:347.
57. Moreira LB, Kasetsuwan N, Sanchez D, et al. Toxicity of topical anesthetic agents to human keratocytes in vivo. J Cataract Refract Surg. 1999;25:975-980.
58. Rapuano CJ. Topical anesthetic abuse: a case report of bilateral corneal ring infiltrates. J Ophthalmic Nurs Technol. 1990;9:94-95.
59. Bettman JW, Aronson SB, Kagawa CM, et al. The incidence of adverse reactions from steroid/anti-infective combinations. Surv Ophthalmol. 1976;20:281-290.
60. McDonnell PJ, Muir MGK. Glaucoma associated with systemic corticosteroid therapy. Lancet. 1985;2:386-387.
61. Donshik PC. Posterior subcapsular cataracts induced by topical corticosteroids following keratoplasty for keratoconus. Ann Ophthalmol. 1981;13:29-32.
62. Petroutsos G. Corticosteroids and corneal epithelial wound healing. Br J Ophthalmol. 1982;66:705-708.
63. Sudesh S, Laibson PR. The impact of the herpetic eye disease studies on the management of herpes simplex virus ocular infections. Curr Opin Ophthalmol. 1999;10:230-233.
64. Parek JG, Raviv T, Speaker MG. Grossly false applanation tonometry associated with interface fluid in susceptible LASIK patients. J Cataract Refract Surg. 2001;27:1143-1144.
65. Hamilton DR, Manche EE, Rich LF, et al. Steroid-induced glaucoma after laser in situ keratomilieusis associated with interface fluid. Ophthalmology. 2002;109:659-665.
66. Physicians' Desk Reference for Herbal Medicines. 3rd ed. Montvale, NJ: Thomson Healthcare; 2004.
67. Eisenberg DM, Davis RB, Ettner SL, et al. Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. JAMA. 1998;289:1569-1575.
68. Fraunfelder FW. Ocular side effects from herbal medicines and nutritional supplements. Am J Ophthalmol. 2004;138:639-647.
69. Blumenthal M, ed. The Complete German Commission E Monographs Therapeutic Guide to Herbal Medicines. Austin, TX: American Botanical Council; 1998.
70. Subiza J. Allergic conjunctivitis to chamomile tea. Ann Allergy. 1990;65:127-132.
71. Ford MA, Cristea GJ, Robbins WD. Delayed psyllium allergy in three nurses. Hosp Pharm. 1992;27:1061-1062.
72. Schwartz HJ, Arnold JL, Strohl KP. Occupational allergic rhinitis reaction to psyllium. J Occup Med. 1989;31:624-626.
73. Ekatomatis P. Herpes simplex dendritic keratitis after treatment with latanoprost for primary open angle glaucoma. Br J Ophthalmol. 2001;85:1008-1009.
74. Wand M, Gilbert CM, Liesegang TJ. Latanoprost and herpes simplex keratitis. Am J Ophthalmol. 1999;127:602-604.
75. Esmaeli B. Management of excessive tearing as a side effect of docetaxel. Clin Breast Cancer. 2005;5:455-457.
76. Skolnick CA, Doughmann DJ. Erosive conjunctivitis and punctal stenosis secondary to docetaxel (taxotere). Eye Contact Lens. 2003;29:134-154.
77. Fraunfelder FT, Meyer SM. Amiodarone keratopathy. Trans Ophthalmol Soc N X. 1984;36:33-34.
78. Fraunfelder FW, Fraunfelder FT, Jensvold B. Scleritis and other ocular side effects associated with pamidronate disodium. Am J Ophthalmol. 2003;135:219-222.
79. Fraunfelder FW, Fraunfelder FT. Evidence for a probable causal relationship between tretinoin, acitretin, and etretinate and intracranial hypertension. J Neuroophthalmol. 2004;24:214-216.